Can Cosentyx (secukinumab) cause IBD or worsen it?
Cosentyx (secukinumab) is an anti–IL-17A biologic used for several inflammatory conditions. IL-17 pathways are involved in intestinal inflammation, and blocking IL-17 can have mixed effects on the gut. In clinical use, there are reports of inflammatory bowel disease (IBD) developing or flaring in people treated with IL-17 inhibitors, including secukinumab—so it is possible for Cosentyx to contribute to new-onset IBD or worsening of existing disease.
What kinds of gut problems are reported with Cosentyx?
When clinicians talk about possible IBD risk with Cosentyx, the concern is typically about symptoms that look like Crohn’s disease or ulcerative colitis, such as persistent diarrhea, abdominal pain/cramping, blood in the stool, and weight loss. If these symptoms occur after starting treatment, clinicians generally evaluate for IBD and reconsider the biologic if needed.
If someone already has Crohn’s or ulcerative colitis, is it safe to take Cosentyx?
For people with known IBD, the main clinical issue is whether starting (or continuing) an IL-17 inhibitor could aggravate inflammation. Because of reported IBD cases and flares with this drug class, physicians usually take a cautious approach—often coordinating with a gastroenterologist and monitoring closely for symptom changes.
What should patients do if they notice possible IBD symptoms?
Patients should contact their prescriber promptly if they develop persistent diarrhea, blood in stool, significant abdominal pain, or unexplained weight loss while on Cosentyx. These symptoms warrant medical assessment rather than waiting them out, since the right next step may include stopping the drug and treating IBD appropriately.
Are there better alternatives if IBD is the concern?
For patients with psoriasis or other inflammatory diseases who also have IBD, the choice of therapy often shifts toward treatments with stronger evidence of benefit in IBD (rather than IL-17 blockade). The best option depends on which condition is primary, disease severity, and prior treatment history.
Source
Sources
[1] https://www.drugpatentwatch.com/